Get the Stockscreener App
35.20
0.39%
0.17
Immunocore Holdings Plc Adr stock is traded at $35.20, with a volume of 167.13K.
It is up +0.39% in the last 24 hours and down -2.83% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$35.03
Open:
$34.93
24h Volume:
167.13K
Relative Volume:
0.50
Market Cap:
$1.78B
Revenue:
$357.71M
Net Income/Loss:
$-20.10M
P/E Ratio:
-85.11
EPS:
-0.4136
Net Cash Flow:
$28.67M
1W Performance:
+5.44%
1M Performance:
-2.83%
6M Performance:
-2.46%
1Y Performance:
+7.54%
1-Day Range:
$34.54
$35.55
1-Week Range:
$33.00
$35.95
52-Week Range:
$23.15
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
35.21 | 1.77B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | UBS | Sell → Buy |
| Oct-31-25 | Initiated | Wells Fargo | Overweight |
| Sep-18-25 | Resumed | Guggenheim | Neutral |
| Aug-25-25 | Resumed | Jefferies | Buy |
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data - sharewise.com
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Nasdaq
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate - Finviz
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Yahoo Finance
Immunocore (NASDAQ:IMCR) Upgraded at Zacks Research - Defense World
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Immunocore outlines 2026 strategy at J.P. Morgan conference - Investing.com
Immunocore outlines 2026 strategy at J.P. Morgan conference By Investing.com - Investing.com South Africa
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Immunocore (NASDAQ:IMCR) Shares Gap UpWhat's Next? - MarketBeat
UBS assumes coverage on Immunocore stock with Buy rating, $55 target By Investing.com - Investing.com South Africa
UBS assumes coverage on Immunocore stock with Buy rating, $55 target - Investing.com India
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Hudson Bay Capital Management LP Sells 49,382 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Bellevue Group AG Increases Stake in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eschler Asset Management LLP Invests $1.26 Million in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
1,024,288 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Purchased by BVF Inc. IL - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Lowered by Armistice Capital LLC - MarketBeat
Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance - Finviz
Immunocore (NASDAQ:IMCR) Sets New 52-Week High – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 1-Year HighHere's What Happened - MarketBeat
Schroder Investment Management Group Boosts Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore stock hits 52-week high at 40.71 USD By Investing.com - Investing.com India
Immunocore stock hits 52-week high at 40.71 USD - Investing.com
Immunocore (NASDAQ:IMCR) Shares Gap DownHere's What Happened - MarketBeat
Immunocore Holdings stock hits 52-week high at $40.53 - Investing.com
Immunocore Holdings stock hits 52-week high at $40.53 By Investing.com - Investing.com South Africa
Immunocore announces board and executive departures with no reported disagreements - Investing.com
Immunocore (NASDAQ:IMCR) Sets New 1-Year HighStill a Buy? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunocore (NASDAQ:IMCR) Reaches New 52-Week HighWhat's Next? - MarketBeat
Immunocore stock hits 52-week high at 39.5 USD - Investing.com
Immunocore at Jefferies Conference: Strategic Expansion and Innovation By Investing.com - Investing.com South Africa
Immunocore at Jefferies Conference: Strategic Expansion and Innovation - Investing.com
A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy - Sahm
Acadian Asset Management LLC Acquires 72,355 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Fiera Capital Corp Purchases 7,924 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Positive Hepatitis B Trial Data Might Change the Case for Investing in Immunocore Holdings (IMCR) - Sahm
Immunocore reports promising data for HBV treatment candidate By Investing.com - Investing.com South Africa
Immunocore reports promising data for HBV treatment candidate - Investing.com
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting - GlobeNewswire Inc.
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89 - Defense World
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - sharewise.com
State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunocore Holdings Plc Adr Stock (IMCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Option Exercise |
17.46 |
572 |
9,987 |
572 |
| Berman David M | HEAD OF R&D |
Dec 04 '25 |
Sale |
40.26 |
31,341 |
1,261,789 |
0 |
| Berman David M | HEAD OF R&D |
Dec 05 '25 |
Sale |
40.14 |
572 |
22,960 |
0 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Option Exercise |
17.46 |
69,404 |
1,211,794 |
69,404 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Option Exercise |
17.46 |
5,521 |
96,397 |
5,521 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Sale |
40.12 |
69,404 |
2,784,488 |
0 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Sale |
40.09 |
5,521 |
221,337 |
0 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Option Exercise |
17.46 |
18,020 |
314,629 |
18,020 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Option Exercise |
17.46 |
100 |
1,746 |
100 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Sale |
40.03 |
18,020 |
721,341 |
0 |
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):